Dark

Check out our Level2View

ACRX
AcelRx Pharmaceuticals, Inc
stock NASDAQ

Inactive

Jan 9, 2024

0.8600USD+7.500%(+0.0600)243,567

Pre-market

0.00USD-100.000%(-0.80)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 27, 2022

08:36AM EST AcelRx Announces Publication Of Article Highlighting Utility Of Sufentanil Sublingual Tablet In Pain Medicine Procedures RTTNews

08:31AM EST AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the PR Newswire

Jan 12, 2022

08:36AM EST AcelRx Pharmaceuticals Highlights Publication Of On Potential Advantages Of The Sufentanil Sublingual Tablet In Joint Replacement Surgery In Journal of Orthopaedic Experience and Innovation Benzinga

08:35AM EST AcelRx Announces Publication Of Editorial By Internationally Recognized Leader In Opioid-Sparing Surgery RTTNews

08:31AM EST Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery PR Newswire

Jan 10, 2022

08:31AM EST AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell PR Newswire

Dec 15, 2021

08:42AM EST ACRX:Data Shows Reduced Hospital Stay &Opioid Utilization With Use Of Sublingual Sufentanil In Joint Replacement Surgery RTTNews

08:36AM EST AcelRx Pharmaceuticals Announces Publication Of Clinical Data Showing Reduced Hospital Length Of Stay And Reduced Opioid Utilization With Use Of Sublingual Sufentanil In Total Joint Replacement Surgery Benzinga

08:31AM EST Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery PR Newswire

Nov 23, 2021

05:11PM EST AcelRx Pharmaceuticals Appoints Jill Broadfoot To Its Board Of Directors RTTNews

05:10PM EST AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board PR Newswire

Nov 15, 2021

11:53AM EST AcelRx Pharmaceuticals Earnings Perspective: Return On Capital Employed Benzinga

11:07AM EST Earnings Scheduled For November 15, 2021 Benzinga

10:51AM EST AcelRx Announces $14M Registered Direct Common Stock and Warrant Offering Benzinga

10:48AM EST AcelRx Pharmaceuticals To Acquire Lowell Therapeutics For ~$32.5M Plus Net Cash Acquired And Certain Other Adjustments Benzinga

10:48AM EST AcelRx Pharmaceuticals Q3 EPS $(0.07), Sales $1.90M, Both Inline Benzinga

10:37AM EST The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More Benzinga

06:50AM EST AcelRx Reports $14 Mln Registered Direct Common Stock And Warrant Offering RTTNews

06:45AM EST AcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering PR Newswire

06:20AM EST AcelRx Pharma Posts Narrower Loss In Q3; To Acquire Lowell RTTNews

06:04AM EST AcelRx Pharma Q3 Loss Per Share $0.07; Announces Execution Of Definitive Merger Deal To Acquire Lowell Therapeutics RTTNews

06:01AM EST AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter PR Newswire

Nov 12, 2021

10:58AM EST AcelRx Pharmaceuticals's Earnings: A Preview Benzinga

Nov 10, 2021

08:31AM EST AcelRx to Host Third Quarter 2021 Financial Results Call and Webcast on PR Newswire

Oct 4, 2021

12:06PM EDT How Bad Are AcelRx Pharmaceuticals's Earnings? | Return On Capital Employed Benzinga

07:30AM EDT Adamis Pharmaceuticals Corporation(Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the companys board of directors. Dr. Desai replaces Roshawn Blunt, who retired from the Board effective October 1, 2021. GlobeNewswire Inc

Sep 10, 2021

03:20PM EDT AcelRx Pharmaceuticals to Participate in Two September Investor Conferences PR Newswire

Sep 2, 2021

08:03AM EDT Acurx Pharmaceuticals To Join Russell Microcap Index Benzinga

Aug 30, 2021

08:35AM EDT AcelRx: Results Announced During Presentation On Effect Of Sufentanil Sublingual Tablet On Outpatient Plastic Surgery RTTNews

08:31AM EDT AcelRx Pharmaceuticals Highlights Presentation Of Results Of Study Evaluating Sufentanil Sublingual Tablets On Outpatient Plastic Surgery At Annual Miami Cosmetic Surgery Event Benzinga

08:31AM EDT Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event PR Newswire

Aug 26, 2021

08:32AM EDT AcelRx To Present On Effect Of Administration Of Sufentanil Sublingual Tablet On Reducing Post-Operative Recovery Time And Opioid Use In Plastic Surgery At The Annual Miami Cosmetic Surgery Event Aug. 27 Benzinga

08:31AM EDT Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event PR Newswire

Aug 19, 2021

06:01AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 5.30 A.M. EDT). RTTNews

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

06:23AM EDT HC Wainwright & Co. Maintains Buy on AcelRx Pharmaceuticals, Lowers Price Target to $5 Benzinga

Aug 16, 2021

04:43PM EDT AcelRx Pharmaceuticals: Q2 Earnings Insights Benzinga

04:04PM EDT AcelRx Pharmaceuticals Q2 EPS $(0.08), Inline, Sales $400.00K Miss $1.81M Estimate Benzinga

04:04PM EDT AcelRx Pharma Q2 Loss/share $0.08, Same As Last Year RTTNews

04:01PM EDT AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results PR Newswire

04:04AM EDT Earnings Scheduled For August 16, 2021 Benzinga

Aug 9, 2021

08:31AM EDT AcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August PR Newswire

Jul 26, 2021

03:12PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Jul 14, 2021

09:28AM EDT AcelRx, Aguettant Ink Licensing Agreements For Dzuveo And Two Prefilled Syringe Products Benzinga

08:47AM EDT AcelRx Pharmaceuticals Inc. (ACRX) said that it has reached agreements with Laboratoire Aguettant providing Aguettant with a license to commercialize DZUVEO in Europe, and providing AcelRx with two pre-filled syringe product candidates for the U.S. RTTNews

08:43AM EDT AcelRx Reaches Deal For DZUVEO In Europe And In-licensing Deal For Two Products In U.S. RTTNews

08:32AM EDT AcelRx Enters into Licensing Agreement for DZUVEO(r) in Europe and In-licensing PR Newswire

08:31AM EDT AcelRx Pharmaceuticals Shares Move Higher; Says Enters Into Licensing Agreement For DZUVEO In Europe And In-Licensing Agreement For 2 Products In U.S. Benzinga

Jul 8, 2021

10:02AM EDT FREQ, ACRX & RLX Shareholder Alert: Bronstein, Gewirtz & Grossman GlobeNewswire Inc

Jul 7, 2021

08:29PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Jun 17, 2021

08:41AM EDT AcelRx Enters Agreement With FDA Addressing Warning Letter Received For DSUVIA Promotional Materials RTTNews

08:34AM EDT AcelRx Reports Deal With FDA To Address Warning Letter Received For DSUVIA Promotional Materials Benzinga

08:31AM EDT AcelRx Announces Agreement with FDA Addressing the Warning Letter Received for PR Newswire

Jun 15, 2021

05:30PM EDT Gainey McKenna & Egleston announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. (AcelRx) (NASDAQ: ACRX) in the United States District Court for the Northern District of California on behalf of those who purchased or otherwise acquiredAcelRx publicly traded securities between March 17, 2020 and February 12, 2021, inclusive (the Class Period). GlobeNewswire Inc

Jun 14, 2021

07:56PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Jun 8, 2021

05:25PM EDT Pomerantz Law Firm Announces the Filing of a Class Action Against AcelRx PR Newswire

Jun 1, 2021

08:31AM EDT of DSUVIA(r) For Analgesia in Plastic Surgery Procedures at the California Society of Plastic Surgeons Annual Meeting PR Newswire

May 26, 2021

09:50AM EDT AcelRx Announces Presentation On Use Of DSUVIA For Plastic Surgery Procedures Selected For "Best Papers" Session RTTNews

08:42AM EDT AcelRx Pharmaceuticals Announces Upcoming Presentation On DSUVIA Titled 'Best Papers of the Regional Societies' May 31 Benzinga

08:31AM EDT for "Best Papers" Session at the California Society of Plastic Surgeons Annual Meeting PR Newswire

May 20, 2021

08:51AM EDT AcelRx Announces Investigator-initiated Study To Be Conducted At Tampa General Hospital To Evaluate DSUVIA RTTNews

08:33AM EDT AcelRx Pharma Reports Will Enroll 100 Patients For Study Conducted At Tampa General Hospital To Evaluate Use Of DSUVIA Pain Mgmt. For Patients With Sickle Cell Disease Benzinga

08:31AM EDT AcelRx Announces an Investigator-Initiated Study of DSUVIA(r) in the Emergency PR Newswire

May 18, 2021

11:52AM EDT AcelRx Pharmaceuticals shares were trading lower after the company reported worse-than-expected Q1 sales results. Benzinga

May 17, 2021

04:40PM EDT AcelRx Pharmaceuticals: Q1 Earnings Insights Benzinga

04:15PM EDT AcelRx Pharmaceuticals Q1 EPS $(0.08), Inline, Sales $500.00K Miss $1.06M Estimate Benzinga

04:06PM EDT AcelRx Pharma Q1 Loss/share $0.08 Vs. Loss $0.20 Year Ago RTTNews

04:02PM EDT AcelRx Pharmaceuticals Reports First Quarter 2021 Financial Results PR Newswire

04:10AM EDT Earnings Scheduled For May 17, 2021 Benzinga

May 13, 2021

10:18AM EDT AcelRx's Dsuvia Shows Reduction In Postoperative Opioids Compared To Control Group Benzinga

09:49AM EDT AcelRx : Study Of DSUVIA Showing Reduction In Postoperative Opioids And Better OBAS Scores Compared To Control Group RTTNews

08:37AM EDT AcelRx Pharma Highlights Poster Presentation At Regional Anesthesiology and Acute Pain Medicine Meeting To Review Results Of Study On Intraoperative Admin. Of DSUVIA 30 mcg For Mgmt. Of Acute Pain Benzinga

08:31AM EDT Better OBAS Scores Compared to Control Group to be Presented at the American Society of Regional Anesthesia (ASRA) Annual Meeting PR Newswire

May 10, 2021

04:06PM EDT AcelRx to Host First Quarter 2021 Financial Results Call and Webcast on May 17, PR Newswire

May 6, 2021

08:54AM EDT AcelRx Announces Investigator-Initiated Study Of DSUVIA For Use In Same-Day Total Joint Replacement Benzinga

08:31AM EDT AcelRx Announces an Investigator-Initiated Study of DSUVIA(r) for Use in PR Newswire

Apr 8, 2021

10:40AM EDT AcelRx To Test Dsuvia In Patients On Buprenorphine Requiring A Surgical Procedure Benzinga

08:47AM EDT AcelRx Announces Investigator-Initiated Study Of DSUVIA In Patients Taking Buprenorphine Who Require A Surgical Procedure Benzinga

08:47AM EDT CORRECTION: AcelRx Pharmaceuticals Ticker Is 'ACRX' Benzinga

08:37AM EDT AcelRx Announces Investigator-Initiated Study Of DSUVIA In Patients Taking Buprenorphine Who Require A Surgical Procedure Benzinga

08:31AM EDT AcelRx Announces an Investigator-Initiated Study of DSUVIA(r) in Patients PR Newswire

Mar 31, 2021

08:32AM EDT AcelRx Appoints Marina Bozilenko As An Independent Member Of Board RTTNews

08:31AM EDT AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board PR Newswire

Mar 29, 2021

09:19AM EDT ROCE Insights For AcelRx Pharmaceuticals Benzinga

Mar 25, 2021

02:45PM EDT Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference Benzinga

08:42AM EDT AcelRx Announces Publication Of Pooled Analysis Of Phase 3 Data On Use Of DSUVIA For Acute Pain Management RTTNews

08:33AM EDT AcelRx Highlights Publication Of Pooled Analysis Of Phase 3 Data On Use Of DSUVIA For Acute Pain Mgmt. In Postoperative, Emergency Dept. Settings In 'Journal Of Pain Research' Benzinga

08:31AM EDT Healthcare Professional and Patient Satisfaction Following Use of DSUVIA(r) for Acute Pain in Hospital Settings PR Newswire

Mar 24, 2021

09:46AM EDT From BZ Biotech Conference: AcelRX CEO Angotti Notes Four-Pillar Strategy For Growth; Pillar 1 Is DoD, Pillar 2 Is Commercial Partnerships In Specialty Markets, Pillar 3 Is Hospital And ASC Penetration And Pillar 4 Is Product Acquisition And In-Licensing Benzinga

09:43AM EDT From BZ Biotech Conference: AcelRX CEO Vincent Angotti Says Believes That As Elective Surgeries Begin To Ramp In 2H 2021, DSUVIA Is Well Positioned To Help With Patient Throughput Benzinga

09:40AM EDT From BZ Biotech Conference: AcelRX CEO Vincent Angotti Says August 2020 Publication Showed Reduced Opioid Use And Time In Post-Anesthesia Care Unit When Administering DSUVIA Benzinga

09:35AM EDT From BZ Biotech Conference: AcelRX CEO Vincent Angotti Highlights 2018 FDA Approval Of DSUVIA, Notes DoD Provided $22M Supporting Development Of Drug; Says Drug Has Been Developed With Attention To Diversion Issues And Tamper-Evident Packaging Benzinga

09:34AM EDT From BZ Biotech Conference: AcelRX CEO Vincent Angotti Says Sublingual Sufentanil Solves Shortcomings With IV Morphine And Fentanyl/Sufentanil; Note Risk Of Extreme Side Effects Is Minimized Benzinga

09:31AM EDT From BZ Biotech Conference: AcelRX CEO Vincent Angotti Highlights 'Clinical Shortcomings' Of IV Opioids And IV Fentanyl/Sufentanil Benzinga

Mar 23, 2021

07:12PM EDT Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021 Benzinga

Mar 22, 2021

02:49PM EDT AcelRx Announces Presentation and Fireside Chat at the Benzinga Biotech Small PR Newswire

Mar 16, 2021

08:17AM EDT The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study Benzinga

Mar 15, 2021

05:21PM EDT AcelRx Pharmaceuticals Q4 Loss/share $0.10 Vs. Loss $0.18 Year Ago RTTNews

04:54PM EDT AcelRx Pharmaceuticals: Q4 Earnings Insights Benzinga

04:02PM EDT AcelRx Pharma Sees FY21 Capex $4M-$5M Benzinga

04:02PM EDT AcelRx Pharmaceuticals Q4 EPS $(0.10), Inline, Sales $738.00K Miss $1.73M Estimate Benzinga

04:01PM EDT AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial PR Newswire

04:53AM EDT Earnings Scheduled For March 15, 2021 Benzinga

Mar 14, 2021

08:14AM EDT Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations Benzinga

Mar 8, 2021

04:06PM EST AcelRx to Host Fourth Quarter and Full Year 2020 Financial Results Call and PR Newswire

Feb 18, 2021

09:47PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of PR Newswire

Feb 17, 2021

08:39AM EST AcelRx Announces Investigator-Initiated Study Of DSUVIA In Patients Undergoing Plastic Surgery Procedures Benzinga

08:31AM EST AcelRx Announces an Investigator-Initiated Study of DSUVIA(r) in Patients PR Newswire

Feb 16, 2021

11:16AM EST AcelRx Says Believes It Can Easily Address Concerns In Warning Letter From FDA Without A Material Impact To Co; Says Plans To Review Its Marketing Materials To Identify Any Potential Revisions Benzinga

10:33AM EST FDA Says Issues Warning To AcelRx For 'Making False And Misleading Claims About Risks And Benefits Of Dsuvia;' Says Co Disseminated Promotional Communications That Undermine Key Prescribing Conditions Required For Safe Use Of Its Opioid Product Benzinga

Jan 26, 2021

10:04AM EST ROCE Insights For AcelRx Pharmaceuticals Benzinga

Jan 20, 2021

09:04AM EST AcelRx Prices $27.5 Mln Public Offering Of Common Stock RTTNews

09:03AM EST AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock PR Newswire

09:02AM EST UPDATE: AcelRx Offering Priced At $1.896/Share Benzinga

09:01AM EST AcelRx Pharma Prices 14.5M Share Offering For Gross Proceeds $27.5M Benzinga

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 19, 2021

04:03PM EST AcelRx Announces An Common Stock Offering; No Terms Disclosed Benzinga

04:01PM EST AcelRx Announces Underwritten Public Offering of Common Stock PR Newswire

08:58AM EST AcelRx Pharmaceuticals Awarded U.S. Patent 'Storage and dispensing devices for administration of oral transmucosal dosage forms' Benzinga

08:34AM EST AcelRx Announces Investigator-Initiated Study Of DSUVIA In Cardiac Surgery Enhanced Recovery Regimen Benzinga

08:32AM EST AcelRx Announces an Investigator-Initiated Study of DSUVIA(r) in Cardiac PR Newswire

Jan 15, 2021

04:40PM EST Are You Following Analysts On These Penny Stocks? Benzinga

Jan 14, 2021

08:42AM EST AcelRx Announces Year-End 2020 Metrics And Review of 2020 Achievements Benzinga

Jan 13, 2021

10:30AM EST ROCE Insights For AcelRx Pharmaceuticals Benzinga

07:25AM EST The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations Benzinga

Jan 12, 2021

11:43AM EST AcelRx, NuCana Shares Spike Higher; Traders Circulate Tipranks Article Titled 'These 2 Penny Stocks Could Surge Over 300%, Say Analysts' Benzinga

Dec 10, 2020

09:11AM EST AcelRx Announces Publication Of Clinical Data On Decreased Postoperative Opioid Requirements RTTNews

09:06AM EST AcelRx Highlights Publication Of Clinical Data On Dereased Postoperative Opioid Requirements, Enhanced Postanesthesia Recovery Following Perioperative Use OF DSUVIA Benzinga

09:03AM EST Postoperative Opioid Requirements and Enhanced Postanesthesia Recovery Following Perioperative Use of DSUVIA(r) PR Newswire

08:31AM EST AcelRx Announces $10M Registered Direct Common Stock Offering; 8.33M Shares At $1.20/Share Benzinga

08:31AM EST AcelRx Announces $10 Million Registered Direct Common Stock Offering PR Newswire

Dec 9, 2020

12:20PM EST AcelRx Pharmaceuticals to Present at LD Micro Main Event PR Newswire

Dec 4, 2020

08:32AM EST AcelRx Announces Partnership With The National Rural Health Association RTTNews

08:31AM EST AcelRx Pharmaceuticals Announces Partnership with the National Rural Health PR Newswire

Nov 18, 2020

08:32AM EST AcelRx Pharmaceuticals Highlights Commentary In Practical Pain Management On Previously Published Clinical Data On Preoperative Administration of DSUVIA Benzinga

08:31AM EST Previously Published Clinical Data on Preoperative Administration of DSUVIA(r) PR Newswire

Nov 6, 2020

01:29PM EST AcelRx Pharmaceuticals to Present at Credit Suisse 29th Annual Virtual PR Newswire

Nov 5, 2020

04:50PM EST AcelRx Pharmaceuticals Q3 EPS $(0.10) Misses $(0.08) Estimate Benzinga

04:07PM EST AcelRx Pharmaceuticals Reports Third Quarter 2020 Financial Results PR Newswire

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

04:06PM EDT AcelRx to Host Third Quarter 2020 Financial Results Call and Webcast on PR Newswire

Oct 27, 2020

03:57PM EDT AcelRx Pharma 13G Filing From BML Investment Partners Shows 5.3% Stake In Co. Benzinga

Oct 6, 2020

04:17PM EDT AcelRx Pharmaceuticals Says On Oct. 1 Entered Promotion Agreement With La Jolla Pharmaceutical Company Pursuant To Which Co.s Restructured Co-Promotion Arrangement To Promote DSUVIA Benzinga

Sep 29, 2020

08:31AM EDT AcelRx to Host Virtual KOL Event on Perioperative Use of DSUVIA(r) PR Newswire

Sep 22, 2020

08:37AM EDT AcelRx Awarded $3.6M US Army Contract For DSUVIA Benzinga

08:33AM EDT U.S. Army Awards AcelRx With Initial Contract Of Up To $3.6 Mln For Purchase Of DSUVIA RTTNews

08:31AM EDT AcelRx Awarded U.S. Army Contract for DSUVIA(r) PR Newswire

Sep 14, 2020

08:33AM EDT AcelRx Announces DSUVIA Added To US Department Of Defense's Joint Deployment Formulary Benzinga

08:31AM EDT AcelRx Announces DSUVIA(r) Added to the U.S. Department of Defense's Joint PR Newswire

Sep 10, 2020

04:06PM EDT AcelRx Pharmaceuticals to Present at Two Upcoming Conferences PR Newswire

Aug 24, 2020

08:39AM EDT AcelRx Announces an Investigator-Initiated Study of DSUVIA in Orthopedic Patients in the Perioperative Setting Benzinga

08:31AM EDT AcelRx Announces an Investigator-Initiated Study of DSUVIA(r) in Orthopedic PR Newswire

Aug 19, 2020

08:40AM EDT AcelRx Pharmaceuticals Highlights Publication Of Clinical Data On Reduced Opioid Use And Reduced Time In Postanesthesia Care Unit (PACU) Following Preoperative Administration Of DSUVIA Benzinga

08:31AM EDT Use and Reduced Time in the Postanesthesia Care Unit (PACU) Following Preoperative Administration of DSUVIA(r) PR Newswire

Aug 18, 2020

11:53AM EDT CORRECTION: Earlier Headline On Accelerate Diagnostics Partner BioCheck Incorrectly Tagged Ticker 'ACRX' Benzinga

09:59AM EDT Letter To Accelerate Diagnostics Partner BioCheck From Aug. 17 Shows FDA Emergency Use Authorization For BioCheck SARS-CoV-2 IgG and IgM Combo Test Benzinga

Aug 13, 2020

09:03AM EDT Credit Suisse Maintains Underperform on AcelRx Pharmaceuticals, Raises Price Target to $0.84 Benzinga

Aug 10, 2020

04:23PM EDT AcelRx Pharmaceuticals Q2 EPS $(0.08) Beats $(0.14) Estimate, Sales $2.92M Beat $2.02M Estimate Benzinga

04:04PM EDT AcelRx Pharma Q2 Loss/share $0.08 Vs. Loss $0.16 Year Ago RTTNews

04:02PM EDT AcelRx Pharmaceuticals Reports Second Quarter 2020 Financial Results PR Newswire

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 3, 2020

04:06PM EDT AcelRx to Host Second Quarter 2020 Financial Results Call and Webcast on PR Newswire

Jul 23, 2020

08:41AM EDT AcelRx Announces Exclusive Distribution, Promotion Partnership For DSUVIA Benzinga

08:40AM EDT AcelRx Announces Exclusive Distribution and Promotion Partnership for DSUVIA(r) PR Newswire

08:32AM EDT AcelRx Prices 9.43M Share Offering At $1.06/Share Benzinga

08:31AM EDT AcelRx Announces $10 Million Common Stock Offering Priced At The Market PR Newswire

Jul 20, 2020

09:33AM EDT Benzinga's Top Upgrades, Downgrades For July 20, 2020 Benzinga

08:43AM EDT 10 Biggest Price Target Changes For Monday Benzinga

05:11AM EDT 80 Biggest Movers From Friday Benzinga

05:10AM EDT Credit Suisse Downgrades AcelRx Pharmaceuticals to Underperform, Lowers Price Target to $0.69 Benzinga

Jul 16, 2020

05:34PM EDT AcelRx Wins ~$3.5M US Army Medical Research Acquisition Contract For Dsuvia Benzinga

Jul 14, 2020

07:12AM EDT Atlas Technical Consultants Sees Prelim. Q2 Sales $111M-$113M vs $109.25M Est.; Sees FY19 Sales $453M-$468M vs $460.31M Est. Benzinga

Share